July 25, 2016
AbbVie and Bristol-Myers Squibb Company have announced a clinical trial collaboration for evaluating the safety, efficacy, and tolerability of investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) of AbbVie in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen of Bristol-Myers Squibb as a treatment for relapsed extensive-stage small cell lung cancer (SCLC).
“We believe the combination of these cancer-fighting agents may offer patients a new treatment option in a disease with limited therapies. By combining immune-checkpoint inhibitors that prime the body’s immune system to fight cancer cells with Rova-T’s approach to target cancer stem cells, we hope to build on our goal to develop differentiated treatments with therapeutic benefit that elevate the standard of care for small cell lung cancer patients,” said Scott J. Dylla, Ph.D., vice president, research and development, AbbVie.
Jean Viallet, M.D., Global Clinical Research Lead, Oncology, Bristol-Myers Squibb, said: “We are excited to explore the potential benefits of combining Bristol-Myers Squibb’s immunotherapies with a targeted approach like Rova-T in small cell lung cancer where the need for new therapies is particularly acute for this aggressive form of lung cancer. As the science around cancer research continues to rapidly evolve, we are building on our leadership in Immuno-Oncology with numerous collaborations that may help advance new therapies for cancers in need of better options.”AbbVie and Bristol-Myers Squibb Collaborate to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimenlast edit: 2016-08-01T17:30:14+00:00da